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Abstract: Due to their capacity to process different proteins of the extracellular matrix (ECM), matrix
metalloproteinases (MMPs) were initially described as a family of secreted proteases, functioning as
main ECM regulators. However, through proteolytic processing of various biomolecules, MMPs also
modulate intra- and extracellular pathways and networks. Thereby, they are functionally implicated
in the regulation of multiple physiological and pathological processes. Consequently, MMP activity is
tightly regulated through a combination of epigenetic, transcriptional, and post-transcriptional control
of gene expression, proteolytic activation, post-translational modifications (PTMs), and extracellular
inhibition. In addition, MMPs, their substrates and ECM binding partners are frequently modified by
PTMs, which suggests an important role of PTMs in modulating the pleiotropic activities of these
proteases. This review summarizes the recent progress towards understanding the role of PTMs
(glycosylation, phosphorylation, glycosaminoglycans) on the activity of several members of the
MMP family.
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1. MMP Domain Structure and Classification
Matrix metalloproteinases (MMPs) comprise a family of 23 distinct secreted or membrane-anchored
endopeptidases in humans that belong to the metzincin superfamily of metalloproteases. MMPs were
initially described as regulators of the extracellular matrix due to their capacity to degrade ECM
proteins like collagen, gelatin, laminin, aggrecan, fibronectin, elastin, and proteoglycans. Based on
structure and substrate specificity, the MMPs are divided into collagenases (MMP1, MMP8, MMP13),
gelatinases (MMP2, MMP9), stromelysins (MMP3, MMP10, MMP11), matrilysins (MMP7, MMP26),
membrane-type MMPs (MMP14, MMP15, MMP16, MMP17, MMP24, MMP25), and other non-classified
family members (MMP12, MMP19, MMP20, MMP21, MMP23, MMP27, MMP28). MMPs share a
multidomain structure consisting of signal peptide, zymogenic pro-peptide domain, a catalytic domain,
a variable linker ‘hinge’ region and a hemopexin domain. Some MMPs show variation in the domain
arrangements, e.g., MMP7 and MMP26 are lacking the linker and hemopexin domain, MMP23
has a unique cysteine-rich and immunoglobulin-like instead of a hemopexin domain, and the two
gelatinases MMP2 and MMP9 have additional fibronectin type-II-related domains. Membrane-type
MMPs are anchored to the membrane either via glycosylphosphatidylinositol (GPI) or with help of a
transmembrane domain (Figure 1). Additionally, MMPs are distinguished by the highly conserved
HExGHxxGxxH motif in the catalytic domain, which contains three histidines that coordinate the
zinc molecule in the active site, and the PRCGxPD motif identified in the pro-domain whose cysteine
residue coordinates with the active zinc molecule to inhibit proteolysis. Each of these domains is
associated with a specific function and very frequently post-translationally modified. This suggests an
important role of PTMs in modulating the pleiotropic activities of MMPs [1,2].
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Figure 1. MMP multidomain organization. Based on their domain structure, MMPs can be subdivided 
into eight different groups. All MMPs share a common structure comprising a signal peptide (SP), a 
pro-domain (Pro), containing a thiol group (SH), a catalytic domain (Catalytic) with a zinc (Zn) 
binding site, a linker region (Hinge) and a hemopexin domain (Hemopexin), which has a disulfide 
bond (S-S). Exceptions to this are the two gelatinases, which contain three fibronectin repeats (Fi) 
within their catalytic domain and furin-activated MMPs which have a furin-recognition site (Fu) 
within their pro-domain and MMP21 with an additional vitronectin-like insert (Vn). Some membrane-
type MMPs are anchored to the membrane via glycosylphosphatidylinositol (GPI), whereas some 
MT-MMPs have transmembrane (TM) and cytosolic domains (Cy). In type II MT-MMPs, an N-
terminal signal anchor (SA), a cysteine array (CA) domain, and an immunoglobulin-like (Ig-like) 
domain are present. Adapted by permission from “Springer Nature: New functions for the matrix 
metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161–174. Egeblad & Werb, 
Copyright (2002)”. 
2. MMP Substrates and Function 
MMPs are primarily extracellular proteases, supporting the initial concept that they are 
generally associated with degradation and regulation of the ECM, thereby influencing many 
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2. MMP Substrates and Function
MPs are prim rily extracellular proteases, supporting the initial concept that they are generally
associated with degradation and regulation of the ECM, thereby influencing many fundamental cellular
events involving ECM remodeling [2–5]. More recently, it was observed that they also can irreversibly
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process growth factors, cell-surface receptors, cytokines, and chemokines, as well as other MMPs,
other proteases and protease inhibitors and even act inside the cell [6]. The activation or inactivation of
bioactive molecules by MMP proteolytic processing unraveled unexpected roles of these proteases
in the regulation of extra- and intracellular signaling pathways [4,7–9]. Hence, the field of MMP
research progressed from perceiving these enzymes solely as regulators of ECM to the conception
that MMPs are functionally implicated in the regulation of multiple physiological and pathological
signaling processes [8,10]. Accordingly, the physiological relevance of their function is emphasized
by a direct association between altered expression and/or dysregulation of MMPs and development
of pathological conditions, such as chronic inflammatory diseases, vascular diseases, neurological
disorders, and cancer [10,11].
3. Multilayered Regulation of MMP Activity
Since MMPs regulate major physiological processes, a strict spatiotemporal control of their
activity is essential to avoid possible detrimental activities of these proteases. Primarily, expression of
MMPs is regulated at the transcriptional level, keeping these enzymes at very low levels in normal
tissue homeostasis. MMPs share cis-regulatory elements in their promoter sequences, which allow
induction of their expression by stimuli—e.g., in the form of growth factors, cytokines, or hormones.
The cooperation between these cis-regulatory elements, coupled with the integration of multiple
signaling pathways, provides a wide range of potential interactions between transcriptional regulators,
ensuring tissue-specific expression of diverse MMP family members and facilitating a strict control
of MMP transcriptional activity. In addition, transcription of MMP encoding genes is regulated
by epigenetic mechanisms, such as DNA methylation or histone acetylation [4,5,11,12]. At the
post-transcriptional level, regulation of MMP expression is mediated by modulation of mRNA
stability and miRNA-based mechanisms that interfere with MMP expression by either transcriptional
inhibition or mRNA degradation [13–16]. An important level of MMP regulation is achieved at the
post-translational level, since most MMPs are secreted as inactive pro-enzymes. The ‘cysteine-switch’
region in the pro-peptide domain shields the active site, thereby preventing substrate access and
maintaining the enzyme in an inactive state. The activation of proMMPs occurs upon direct
proteolytic cleavage of the pro-domain (within the secretory pathway or extracellularly), or induction
of conformational changes that disrupt the chelating cysteine residue and enable auto-proteolysis for
removal of the pro-domain region [9,12]. Moreover, allosteric activation of proMMPs can be triggered
by interaction with ECM components and cell surface molecules and by low-density lipoprotein
receptor-related protein (LRP1)-mediated endocytosis [12,17–20]. Upon activation, mature MMPs are
exclusively controlled by endogenous inhibitors, such as tissue inhibitors of metalloproteases (TIMPs)
and α2-macroglobulin [21,22].
4. PTMs—An Additional Level of Protein Regulation
The enormous functional complexity of the cellular proteome is regulated by diverse mechanisms,
including transcription, alternative splicing, translation, and PTMs [23]. Among these regulatory
mechanisms, PTMs provide a significant genome-independent expansion and diversification of
the proteome, thereby creating a continuously fine-tuned regulatory network implicated in many
cellular processes [24–26]. Based on the type of modification, PTMs can be assigned to several
categories: chemical modifications, including methylation, phosphorylation, acetylation, and oxidation;
polypeptide modifications, including ubiquitination, SUMOylation and other ubiquitin-like protein
conjugation; modifications by complex molecules, including glycosylation, lipids (e.g., acylation,
prenylation) and extended structures (e.g., glycosaminoglycans (GAGs)); and modifications of the
amino acids or of the polypeptide backbone, including deamidation, eliminylation, and protein cleavage
through proteolysis [27–30]. By reversible or irreversible addition of these functional groups PTMs
can modify protein function by altering protein structure, subcellular localization, protein–protein
interactions, and degradation, thereby influencing many cellular processes in health and disease [31–36].
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Like many enzymes, MMPs as well as their substrates are modified by a variety of PTMs. Different
domains of the MMP structure are associated with specific functions and undergo different, highly
specific PTM modifications, which suggests an important role of PTMs in modulating the pleiotropic
activities of MMPs (Figure 2) [1]. Understanding the influence of specific PTMs on the activity of
MMPs is necessary to fully understand MMP regulation. In this review, we provide an overview of
different PTMs with a focus on glycosylation, phosphorylation, and interaction with extracellular
GAGs, and describe their effects on activity of various MMP family members.
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4.1. Glycosylation of MMP
Glycosylation describes the enzymatic reaction that links saccharides to lipids, other saccharides
or proteins and represents the most abundant and diverse PTM. The most common forms of
protein glycosylation are the N- and O-linked glycosylation [37,38]. N-linked glycosylation is a
glycosidic linkage of glycans to the side chains of asparagine (Asn) residues. It is initiated by a single
oligosaccharyltransferase complex with a transfer of N-acetylglucosamine (GlcNAc) phosphate at the
consensus Asn-Xaa-Ser/Thr sequence (X, indicating any amino acid excluding proline) on the cytosolic
side of the endoplasmic reticulum (ER) and extensively modified further in the lumen of the ER and
Golgi prior to sorting to secretory vesicles [37,39–41]. O-linked glycosylation is a glycosidic linkage of
glycans to the side chains of serine/threonine (Ser/Thr) or tyrosine (Tyr) residues. O-linked glycosylation
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shows a higher diversity thanN-glycans, resulting from the complex synthesis ofN-acetylgalactosamine
(GalNAc)-type O-linked glycans in the Golgi, which can be initiated by up to 20 different polypeptide
GalNAc-transferase isoforms that may compete for the same glycosylation site and the same glycan.
Upon transfer of a GalNAc moiety from a donor substrate uridine diphosphate (UDP)-GalNAc to
Ser/Thr residues, the O-linked glycan is branched out by different core-forming enzymes and further
extended by fucosylation and sialylation to the final O-linked glycan structure [41–45]. Protein
glycosylation regulates essential biological processes, such as protein folding, secretion, cell adhesion,
and inter- and intra-cellular trafficking [46–50]. Consequently, alterations in glycosylation patterns
are often associated with different pathological conditions like neurodegenerative diseases, diabetes,
inflammatory conditions, and cancer [51,52]. The majority of MMPs are glycosylated, and N- and
O-linked glycosylation are present across the MMP family [39]. The following section summarizes the
current structural and functional information about glycosylation of different MMPs.
4.1.1. MMP9
MMP9 is the most extensively glycosylated MMP. This protease contains two N-linked
glycosylation sites, Asn38 and Asn120 (asparagine residues 38 and 120), in the pro-domain and
the catalytic domain, respectively [53]. These N-linked glycans have been described as core-fucosylated
biantennary structures, partially sialylated with variable fucosylation branches [54]. Despite their
similar composition, the individual functions of these N-linked glycosylations are distinct, primarily
due to their location within the protease. Since N-linked glycosylation is generally required for protein
secretion, initially a potential role of these two glycans was related to the secretion of MMP9 [55].
Indeed, abrogation of MMP9 glycosylation at Asn120 reduced the efficiency of its secretion by increasing
the interaction between MMP9 and calreticulin (a protein that prevents misfolded proteins from
entering the secretory pathway), thereby inducing MMP9 retention in the ER. The glycosylation at
Asn38 does not influence the secretion of MMP9, but Asn38-glycosylation-deficient MMP9 shows strong
amino-acid dependency towards interaction with calreticulin, likely affecting MMP9 secretion in an
N-glycosylation-independent manner [56]. Additionally, N-glycosylation at Asn38 was commonly
associated with the activation of proMMP9, yet the process of MMP9 activation occurs independently
of the glycosylation at Asn38. Recent molecular dynamics simulations suggest that the glycosylation
at Asn38 is indirectly involved in the activation of proMMP9 by inducing conformational changes
within the pro-domain, enabling MMP3 to access the two cleavage sites for proteolytic activation [57].
Moreover, interactions between the glycosylation at Asn38 and galectin 3 decrease the proteolytic
activation of MMP9, whereas interactions with galectin 8 enhance the MMP3-mediated processing,
suggesting that the presence of N-glycosylation is important for a fine-tuned regulation of MMP9
activity [58,59]. Furthermore, MMP9 has a proline-rich linker sequence between the active site
and the hemopexin domain, which contains 14 O-linked glycans (denominated OG domain) [60].
Based on their glycan composition, these O-linked glycans comprise a heterogenic mixture, varying
from core-1 (Galβ1-3GalNAc) to core-2 (Gal-(GlcNAc-)GalNAc) structures and further elongated
to larger glycans [61]. The presence of these O-linked glycans increases the domain flexibility of
MMP9, allowing the protease to adopt multiple enzyme conformations and facilitating individual
movements of the catalytic and the hemopexin domain. This influences the recognition, binding, and
processing of substrates, cell receptors, and endogenous inhibitors [62,63]. A study by den Steen et
al. described that the OG domain is indispensable for correct orientation of the hemopexin domain
for MMP9 internalization and degradation by LRP-1 and LRP-2, as well as inhibition by endogenous
TIMP1 [60]. Consequently, deletion of this linker region significantly reduced the affinity towards
TIMP1 and disrupted the interactions with LRP-1 and LRP-2 [60]. However, since deletion of the OG
domain did not affect the activity of MMP9, the authors reported that the OG domain functions as a
regulator of extracellular bioavailability of the protease, rather than as a regulator of its activity [60].
An independent analysis of MMP9 lacking the OG domain performed by Vandooren et al. showed a
reduced gelatinolytic activity of the truncated protease [64]. Furthermore, a study by Dufour et al.
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reported reduced MMP9-induced cell migration in endothelial cells expressing MMP9 without the OG
domain, which was independent of the proteolytic activity of the enzyme [26].
4.1.2. MMP14
Similar to MMP9, the transmembrane collagenase MMP14 (MT1-MMP) contains O-linked
glycosylation sites (Thr291, Thr299, Thr300, and Ser301) identified in the linker region. The presence
of these O-linked glycans does not affect zymogen activation, collagenase activity or the autolytic
processing of MMP14. However, the O-linked glycosylation is important for the formation of a stable
complex between MMP14, TIMP2, and proMMP2, which is required for subsequent cell-surface
activation of MMP2. Being unable to recruit TIMP2, which connects the catalytic domain of MMP14
and the hemopexin domain of proMMP2, the glycan-deficient MMP14 cannot present a stable trimeric
complex on the cell surface and thereby activate MMP2 [65–67]. Interestingly, although it has not
appeared that glycosylation could directly affect MMP14 activity, recent reports describe increase of
MMP14 activity upon alterations in the glycosylation pattern. Indeed, hyper-glycosylation of MMP14
led to higher proteolytic activity and promoted tumor growth [68].
4.1.3. MMP1
MMP1 has two potential glycosylation sites in the active site, but only N-glycosylation at Asn120
has been experimentally confirmed. Comparison between the glycosylated and non-glycosylated
MMP1 showed no significant differences in activity, substrate specificity or inhibitory profiles of the
two proteoforms. However, the presence of specific glycan motifs (e.g., α1,3-fucosylated LacdiNAc)
can initiate MMP1 selectin-mediated binding to the surface of activated cells through a selectin/glycan
interface and therefore may have a profound effect on cell migration [39,69].
4.1.4. MMP2
MMP2 has two potential N-linked glycosylation sites, Asn573 and Asn642, in the hemopexin
domain [70,71]. The function of these N-linked oligosaccharides remains unclear. However, there are
strong implications regarding their involvement in the regulation of MMP2, since the hemopexin
domain is involved in MMP2 activation/inhibition, localization of its catalytic activity, and induction of
cell signaling upon interaction of MMP2 with cell-surface receptors [71,72].
4.1.5. MMP3
Based on the consensus sequence for N-linked glycosylation, MMP3 also has two potential
N-linked glycosylation sites, Asn120 in the catalytic domain and Asn398 in the hemopexin domain.
However, only a small portion of MMP3 (~20%) is glycosylated, and no correlation has been established
between these glycans and the function of the protease [39,73].
4.1.6. MMP13
MMP13 was shown to be potentially glycosylated at two asparagine residues (Asn117 and Asn152)
in the catalytic domain. The N-linked glycosylation site at Asn117 has been experimentally verified,
but the function of this N-linked glycan has not been determined since no differences were observed
between glycosylated and non-glycosylated recombinant MMP13 [74,75].
4.1.7. MMP17
MMP17 (MT4-MMP), a glycosylphosphatidylinositol-anchored matrix metalloproteinase, has two
N-linked glycans at Asn137 and Asn318 in the catalytic site and the linker region, respectively.
The presence of these N-linked oligosaccharides stabilizes the dimeric form of MMP17 by promoting
non-covalent interactions or facilitating folding and formation of disulfides [76–78].
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4.2. Phosphorylation of MMPs
Protein phosphorylation is one of the most important PTMs for regulation of biological
processes [79]. This dynamic PTM is characterized by the reversible enzymatic addition of a phosphate
group to amino acid side chains of serine (Ser), threonine (Thr), or tyrosine (Tyr), resulting in alterations
of protein structure, stability, and dynamics [79]. Hence, phosphorylation can initiate different
conformational changes associated with differential activity and binding specificity, leading to an
activation or deactivation of proteins [80,81]. Furthermore, the dynamic nature of phosphorylation
resulting from the opposing activities of kinases (which add phosphate groups) and phosphatases
(which remove phosphate groups) is functionally compatible with the modulation of intramolecular
interactions, implicated in essential cellular processes, such as cell division, cellular proliferation and
differentiation, apoptosis, and signal transduction [79]. Consequently, dysregulation of phosphorylation
dynamics is often related with pathologies, e.g., tumor formation, chronic inflammatory diseases,
autoimmune diseases, and neurodegenerative disorders [81,82].
As many secreted and extracellular proteins, the MMPs are phosphorylated. Ser-, Thr-, and Tyr
phosphorylation sites are identified across the different structural domains of the MMPs. Yet,
the biological significance of these phosphate groups is overall poorly characterized. Among the
MMPs, MMP2 and membrane-type MMP14 metalloproteinase are the ones with most extensively
studied phosphorylation-dependent effects.
4.2.1. MMP2
MMP2 contains 29 potential phosphorylation sites distributed across the pro-peptide domain,
collagen-binding domain, collagenase-like domain-1 and -2, and hemopexin domain. However,
only five of the predicted phosphorylation sites (S32, S160, Y271, T250, and S365) have been confirmed
by mass spectrometry (MS). The phosphorylation of MMP2 noticeably diminishes its proteolytic
activity, while dephosphorylation increases MMP2 activity. This is possibly due to the conformational
changes observed in the secondary structure of dephosphorylated MMP2, with α-helices 50% longer
and β-strands 17% shorter than phosphorylated MMP2. However, it is still unclear if protease activity
is directly influenced by these conformational changes [83,84].
4.2.2. MMP14
MMP-14 phosphorylation is known to play an important role in fine-tuning the activity of MMP14
at the cell surface and in the activation of intracellular signaling, and it is critical for regulating the
pro-metastatic function of this metalloproteinase. This membrane-type metalloprotease has nine
potential phosphorylation sites in its multidomain structure (PhosphoSitePlus [85], UniProt [86]).
The cytoplasmic domain of MMP14 regulates its internalization and trafficking, thereby modulating
enzymatic activity at the cell surface. A study by García-Pardo et al. reported that this domain
was essential for MMP14 mediated cellular invasion and migration [72]. The cytoplasmic domain of
MMP14 contains two phosphorylation sites, at Thr567 and Tyr573, which have a significant influence on
MMP14-induced cellular invasion and migration. A study by Williams et al. in fibrosarcoma cells
showed that substitution of the residue Thr567 by alanine increased retention at the cell surface and
reduced internalization of the protease significantly compromising invasion and migration. Contrarily,
mimicking protease phosphorylation by substitution of Thr567 by glutamic acid reduced retention of
MMP14 at the cell surface, increased efficiency of internalization, and was correlated with an increase
in migration and invasion [87]. A study by Moss et al. showed that phospho-mimetic Thr567 mutants
exhibit higher collagenolytic activity and three-dimensional growth within a collagen matrix, thereby
promoting enhanced matrix invasion in ovarian cancer cells [88]. In addition, phosphorylation of
Thr567 impacted the integrity of cell monolayer, cell motility and multicellular aggregate dynamics
in ovarian cancer cells, promoting metastasis-associated behaviors [89]. Furthermore, a study
by Nyalendo et al. reported that phosphorylation at Tyr573 influenced cell migration, suggested
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by the ability of a phospho-defective mutant to inhibit migration of cells endogenously expressing
MMP14 [90]. Additionally, epidermal growth factor (EGF)-induced phosphorylation of Tyr573 prompted
internalization of MMP14 together with pericellular collagen, establishing an environment for expansive
growth in three–dimensional collagen matrix, whereas lack of responding to EGFR signaling triggered
invasive growth. Therefore, the phosphorylation of Tyr573 modulates cell surface dynamics of MMP14,
thereby regulating the transition between invasive and expansive growth [91].
4.2.3. Extracellular Phosphorylation of MMPs
A subset of MMPs (MMP1, 12, 13, 14, 16, 24, and 27) are tyrosine phosphorylated by the
extracellular vertebrate lonesome kinase (VLK). These phosphotyrosines are found exclusively within
the hemopexin domains of the MMPs. Interestingly, proteins distantly related to MMPs, which contain
hemopexin-like domains, were found to be tyrosine phosphorylated at identical positions by VLK.
The structural conservation of these phosphorylation sites suggests that they play a role in regulating
MMP activity, a potential function, which still remains largely undiscovered [92,93]. Additionally,
a study by Bordoli et al. showed that co-expression of VLK with MMPs supported their tyrosine
phosphorylations that have been extensively observed in vivo. Bordoli also showed that by introducing
a mutation in the ATP binding site of VLK or deletion of the proline glycine-rich domain (a conserved
domain close to the kinase domain), the phosphorylation of the MMPs and other co-expressed substrates
in the extracellular environment was eliminated. Similarly, shRNA-mediated downregulation of VLK
expression and substitution of Tyr360 with phenylalanine in MMP1 reduced MMP13 and MMP1 tyrosine
phosphorylation, respectively [93]. While VLK generates the majority of extracellular phosphotyrosines,
additional secreted kinases have been identified, which may also be responsible for the extracellular
protein phosphorylation events observed in vivo. This indicates a major impact of the secreted kinome
on tissue homeostasis and disease pathogenesis. Discovery of novel extracellular kinases, identification
of their substrates, and dissection of the regulatory mechanisms involved will provide us with a better
understanding of their functions [94–96].
4.3. Glycosaminoglycans
An additional layer of regulation of extracellular proteolysis is mediated by interactions of MMPs
with glycans in the extracellular space rather than direct glycosylation or phosphorylation of the
protease or substrate. Glycosaminoglycans (GAGs) are extracellular glycans, which are composed
of linear, unbranched repeats of disaccharide units. Heparan sulfate (HS) is a GAG-family member
expressed by virtually every cell of a multicellular organism composed of repeats of glucoronic acid
(GlcA) and N-acetylglucosamine (GlcNAc) dimers, which in most cases are attached to a cell-membrane
associated core protein. During GAG-chain synthesis HS undergoes several sulfotransferase-mediated
N- and O-sulfations. These modifications do not undergo completion, which results in strongly
negatively charged sugar chains with variable length and degree of sulfation interrupted by stretches
of unmodified, neutral regions. The sulfated regions bind basic peptide motifs of many signaling
molecules, including morphogens (Hedgehogs, Wnts, TGFs), cytokines, and most chemokines [97–99].
This electrostatic interaction leads to partial neutralization of the protein surface and can have different
effects on the biological functions of the interacting protein by facilitating, enhancing, or inhibiting
the interaction with other proteins. It is important to note that these interactions, even though
they are mainly based on electrostatics, are in most cases very specific and do not occur randomly.
This is shown by the fact that many proteins contain specific GAG-binding motifs, with which they
exclusively bind HS, even though they contain many lysine and arginine residues (for an in-depth
review of the molecular basis of HS-protein interactions see Xu & Esko, 2014 [100]). Examples
of HS-binding proteins are members of the fibroblast growth factor (FGF) family. Here, HS is
part of the trimeric FGF/FGF-receptor/HS co-receptor complexes and activates FGF signaling in a
sulfation pattern-dependent manner [101–104]. HS-induced oligomerization has been shown in many
other processes including dimerization of amyloid precursor protein (APP) complexes or nearly all
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chemokines [105–108]. Interestingly, HS does not only mediate protein complex formation, but many
proteins binding to HS, including the aforementioned candidates, are also known to undergo proteolytic
processing on or near the cell surface. This indicates a crucial role of HS in regulating extracellular
cleavage processes.
4.3.1. GAG-regulated Substrate Proteolysis
Signaling processes in the extracellular space usually involve at least one form of substrate
proteolysis. Therefore, co-factors have to act as decision makers to ensure regulated processing of
signaling proteins. Multiple cases have been reported, where this is mediated by substrate binding to
GAGs. For example, similar to N-glycans, GAGs can modulate the stability of substrates. FGF2 binding
to heparin, an extremely sulfated HS variant expressed by connective-tissue type macrophages,
stabilizes FGF2 and protects it from degradation by proteolysis [109,110]. The same stabilizing effect
has been shown for the degradation of stromal cell-derived factor 1 (SDF1)/CXCL12 and C-terminal
processing of interferon-γ [111,112]. Despite this stabilizing effect GAGs have been demonstrated to
play additional important roles in extracellular proteolysis. In the case of shedding of morphogens
from the Hedgehog (Hh) family, HS acts as an assembly platform for protease-release complexes [113].
Here, HS recruits Hh co-factors that co-localize proteases and allow for cleavage of the substrate
(Figure 3) [114]. Furthermore, direct HS binding of the N-terminal cleavage site of Hh also has
a stabilizing effect by inhibiting N-terminal Hh processing and reduces its release in vitro and in
Drosophila in vivo [114,115]. An example of how GAG binding can positively regulate substrate
cleavage (Figure 3) was shown for the cleavage of viral capsid proteins. Binding of the human
papillomavirus viral capsid protein L1 to highly sulfated HS is essential to induce a conformational
change and leads to cleavage of L1 by the human trypsin-like serine proteinase kallikrein 8, a process
which is required for virus internalization [116].
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4.3.2. GAG-regulated MMP Activity
GAGs also regulate extracellular proteolysis at the protease level by modulating activation,
localization, and protease–substrate interactions (Figure 3 middle). Many secreted vertebrate MMPs
associate to the cell surface via binding to HS, including MMP9, which is specific, since excess soluble
heparin extracts and solubilizes MMP2, MMP7, MMP9, and MMP13 [117,118]. Moreover, heparin,
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a highly sulfated form of HS, affects protease activity by increasing TIMP3 affinity to MMP2, MMP7,
and MMP9, and HS affects MMP9 expression and plasma levels, depending on its sulfation and
expressing cell type [119–123]. Finally, in vivo studies showed that MMPs in secretory granules of
mast cells interact with heparin and that loss of heparin sulfation reduces MMP stability [124,125].
Like all MMPs, the wound repair and immune reaction associated MMP7 has to be converted into its
proteolytic active form by removal of its inhibitory pro-sequence. MMP7 is able to activate itself by
intermolecular autolytic processing. This is amplified by binding of MMP7 to highly sulfated GAGs
(e.g., heparin or chondroitin sulfate), which significantly increases MMP7 auto-processing and also
increases cleavage of specific physiological substrates [19].
5. Conclusions
MMP biology has been revolutionized with the recognition of extracellular proteolysis not
as a simple mechanism of ECM degradation but as a regulatory mechanism for precise cellular
control of biological processes. The paradigm shift for MMP functions from ECM degradative
proteases to important regulators of essential cellular processes has highlighted the physiological
relevance of these proteases, directly implicated by the relationship between MMP expression and
disease development [4,8]. Hence, the multilayered regulation of MMPs emphasizes the tremendous
importance of the balance between synthesis of active enzymes and their inhibition, which is pivotal to
avoid the destructive activity of these proteases. Characterization of these regulatory mechanisms
will aid the development of new therapeutics for various pathologies. MMP activity is regulated
at the transcriptional level, post-translationally by pro-enzyme activation, by PTMs, and through
extracellular inhibition by TIMPs and by non-specific proteinase inhibitors. Among these regulatory
mechanisms, PTMs have recently obtained wide attention in the MMP community. MMPs are modified
by PTMs at multiple sites (Table 1), which affects the activity of individual MMPs to a different
extent, but the biological relevance of many of them is still unknown. However, many of the studies
referenced in this review have been performed prior to the rapid progression of proteomics method
development within the last decade. Many of the challenges that still limit our understanding of
PTM function in MMP biology can now be approached by modern technologies of state-of-the-art
proteomics. Advances in MS-based methods including multiplexed chemical labeling, novel label-free
quantification strategies, improvement in PTM enrichment, more robust PTM analysis workflows and
streamlined bioinformatics strategies will contribute to reliable identification and quantification of
high numbers of PTMs [126,127]. The remaining challenge lies in defining the functional role of the
physiologically relevant PTMs to understand PTM-dependent activity of MMPs in complex biological
systems [128].
Table 1. List of identified PTMs in MMPs.
MMP Modification Biological Effect Reference
MMP1
N-linked glycosylation at Asn120 Tumor cell invasion and angiogenesis [39,69,129]
Phosphorylation at Tyr360 Not reported [93]
MMP2
O-linked glycosylation at Ser32,
Thr96, 262, 458, 460
Upregulation of MMP2 [39,71,72]
N-linked glycosylation at Asn573 and Asn642 Not reported [130]
Phosphorylation at Ser32, Ser160, Tyr271, Thr250
and Ser365
Phosphorylation decreases, while
dephosphorylation increases protease activity [83,84]
Heparan sulfate Cell surface localization; affects proteaseactivity by increasing TIMP3 affinity [119–122]
MMP3
N-linked glycosylation at Asn120 and Asn398
Not reported [39,73]
Three potential O-linked glycosylation at Ser56,
Ser269 and Thr277
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Table 1. Cont.
MMP Modification Biological Effect Reference
MMP7 Heparan sulfate, Chondroitin sulfate
Cell surface localization; affects protease
activity by increasing TIMP3 affinity; increases
MMP7 auto-processing and activity
[19,120,121]
MMP9
N-linked glycosylation at Asn38 and Asn120 MMP9 secretion and activation [53–59]
O-linked glycosylation in the linker region
Increases the domain flexibility; necessary for
internalization and degradation; protects




Cell surface localization; affects protease
activity by increasing TIMP3 affinity; affects
MMP9 expression and plasma levels
[119–123]
MMP12 Phosphorylation at Tyr414 Not reported [93]
MMP13
N-linked glycosylation at Asn117 and Asn152 Not reported [1,74,75]
O-linked glycosylation at Ser24 and Ser62 Not reported [1,74,75]
Phosphorylation at Tyr366 Not reported [93]
MMP14
N-linked glycosylation at Asn229 and Asn311 Not reported [39]
O-linked glycosylation at Thr291, Thr299, Thr300,
and Ser301
Required for formation of a stable complex
with proMMP2 and TIMP2; increases activity
upon glycosylation perturbation
[65–68]
Phosphorylation at Thr567, Tyr573 and Tyr353
Regulates MMP14 induced cellular invasion
and migration; cell surface dynamics and
internalization; mimetic mutants exhibit higher




MMP16 Phosphorylation at Tyr377 and Tyr521 Not reported [93]
MMP17 N-linked glycosylation at Asn137 and Asn318 Stabilizes the dimeric form of MMP17 [76–78]
MMP24 Phosphorylation at Tyr534 Not reported [93]
MMP27 Phosphorylation at Tyr360 Not reported [93]
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SH Thiol group
SP Signal peptide
Thr Threonine amino acid
TIMPs Tissue inhibitors of metalloproteinases
TM Transmembrane domain
Tyr Tyrosine amino acid
UDP Uridine diphosphate
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